On June 3, WuXi XDC fell 3.01% in regular trading, trading at 53.2 HKD/share, with trading volume of approximately 32.21 million HKD. The stock had rebounded for only two trading days before resuming its downward trajectory.

On the news front, the company previously disclosed that its professional trustee purchased 5.702 million shares on the open market between May 19 and 29 at an average price of 57.3 HKD, with total consideration of approximately 327 million HKD funded entirely from internal resources. Additionally, the company announced a proposal to seek shareholder approval at its AGM to authorize buybacks of up to 10% of issued share capital. Combined with parent WuXi Biologics' up-to-400-million-USD buyback plan, the WuXi group's aggregate repurchase scale reaches 500 million USD. Despite these intensive buyback measures, selling pressure persisted across the sector, with WuXi Biologics declining 4.89% and WuXi AppTec falling 2.54%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)